Massive EPS surprise. Curis, Inc. (NASDAQ: CRIS) reported Q4 2025 GAAP EPS of $1.23 versus the consensus estimate of -$0.43, beating by 384.4%. The biotechnology company swung to profitability with net income of $19.4 million, a sharp reversal from the year-ago loss. Four analysts covered the quarter, with estimates ranging from -$0.72 to -$0.28 per share. The stock traded at $0.89, up from its 52-week low of $0.77 but well below the $3.13 high.
Revenue falls short. Q4 revenue of $1.1 million missed the $3.2 million consensus, falling short by 66%. Revenue declined 67% year-over-year from $3.3 million in Q4 2024. The sharp revenue contraction stands in stark contrast to the profitability surprise, suggesting the EPS beat was driven by non-operating items rather than core business momentum. Trading volume reached 138,507 shares on the report date.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M first appeared on Alphastreet.
